Evidence map›Paper›PMID 38514751›Full record

ArticleScientific reports2024

Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA markers in urothelial bladder cancer patients.

Taku Murakami, Keita Minami, Toru Harabayashi, Satoru Maruyama, Norikata Takada, Akira Kashiwagi, Haruka Miyata, Yasuyuki Sato, Ryuji Matsumoto, Hiroshi Kikuchi and 6 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Taku MurakamiResearch & Development, Showa Denko Materials (America), Inc., Irvine, CA, USA.
Keita MinamiDepartments of Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan.
Toru HarabayashiDepartment of Urology, Hokkaido Cancer Center, Sapporo, Japan.
Satoru MaruyamaDepartment of Urology, Hokkaido Cancer Center, Sapporo, Japan.
Norikata TakadaDepartment of Urology, Hokkaido Cancer Center, Sapporo, Japan.
Akira KashiwagiDepartment of Urology, Teine Keijinkai Hospital, Sapporo, Japan.
Haruka MiyataDepartment of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan.
Yasuyuki SatoDepartment of Urology, Sapporo Keiyukai Hospital, Sapporo, Japan.
Ryuji MatsumotoDepartment of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan.
Hiroshi KikuchiDepartment of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan.
Takashige AbeDepartment of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan.
Yoichi M ItoClinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan.
Sachiyo MuraiDepartment of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan.
Nobuo ShinoharaDepartment of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan.
Hiroshi HaradaDepartments of Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan.
Takahiro OsawaDepartment of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan. taka0573@med.hokudai.ac.jp.
Hokkaido University Hospital · JPSapporo City General Hospital · JPDenso (United States) · USKeiyukai Sapporo Hospital · JPTeine Keijinkai Hospital · JP

Funding

Japan Society for the Promotion of Science 22K09439
6 · The paper itself

Abstract

We designed this multi-center prospective study with the following objectives: (1) the cross-sectional validation of extracellular vesicles (EV) mRNA markers to detect urothelial bladder cancer (UBC) before transurethral resection of bladder cancer (TURBT), and (2) the longitudinal validation of EV mRNA markers to monitor non-muscle invasive bladder cancer (NMIBC) recurrence after TURBT. EV mRNA markers evaluated in this study were KRT17, GPRC5A, and SLC2A1 in addition to two additional markers from literatures, MDK and CXCR2, and measured by quantitative RT-PCR with normalization by a reference gene (ALDOB). Diagnostic performances of EV mRNA markers were compared to conventional markers. Regarding the first objective, we confirmed that EV mRNA biomarkers in urine were higher in UBC patients, particularly those with higher stage/grade tumors, than in those without UBC (n = 278 in total) and the diagnostic performance of EV mRNA MDK and KRT17 outperformed conventional biomarkers with AUC 0.760 and 0.730, respectively. Concerning the second objective, we prospectively analyzed the time courses of EV mRNA markers while NMIBC patients (n = 189) (median follow-up 19 months). The expression of EV mRNA KRT17 was significantly high in patients with recurrence, while it gradually decreased over time in those without recurrence (p < 0.01).

Indexed as

Carcinoma, Transitional CellNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsBiomarkersCross-Sectional StudiesHumansNeoplasm InvasivenessNeoplasm Recurrence, LocalProspective StudiesReceptors, G-Protein-CoupledBiomarkersGPRC5A protein, humanReceptors, G-Protein-CoupledBiomarkerCancer recurrenceExosomeExtracellular vesiclesmRNANon-muscle invasive bladder cancer

Identifiers

PMID38514751
PMCPMC10957914
OpenAlexW4393041480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.